Top Philadelphia, PA Software Companies With Best Stability & Growth (255)

Strong Revenue Growth: Q2 2026 total net revenue rose 4% sequentially to $15.9 billion. Integration of Discover and Brex contributed to higher non‑interest income and broader payments capabilities.

Profitability: Q2 2026 net income reached $3.0 billion, up from $2.2 billion in Q1 2026, alongside a net interest margin of 8.01%. Management also cited strong credit performance, including a $662 million reserve release.

Market Expansion: Acquisition‑driven scale is broadening reach, with the Discover deal (closed May 18, 2025) and Brex (closed April 7, 2026) adding network and corporate card/spend‑management capabilities. Balance‑sheet growth continued in Q2 2026 as period‑end loans rose 2% to $457.2 billion and total assets reached $673.8 billion.

Strong Revenue Growth: A stated milestone of surpassing $100M in contracted annual recurring revenue by end‑2025 and placement on Deloitte’s Technology Fast 500 point to multi‑year top‑line momentum. These indicators align with expanding utilization metrics such as billions of annual patient communications.

Investor Backing & Capital Strength: A $65M growth investment announced in December 2025 is positioned to fund expansion and accelerate AI initiatives. This capital raise underscores confidence from investors in the company’s scaling trajectory.

Strategic Partnerships: Embedded distribution via MEDITECH’s Expanse Patient Connect being powered by the platform and Oracle Health roadmap references extend reach within major EHR ecosystems. These integrations provide channel access and stickiness in enterprise workflows.

Strong Revenue Growth: Recent disclosures point to record quarterly and full‑year revenue with increases in both net interest income and fee income, and management’s 2026 outlook calls for further top‑line expansion. Q2 2026 results specifically noted record revenue with sequential growth in core components.

Profitability: Earnings are described as strong, including $7.0B of net income for full‑year 2025 and $2.1B in Q2 2026. The board’s decision to raise the quarterly common dividend to $2.00 per share signals confidence in ongoing earnings power.

Market Expansion: The acquisition of FirstBank closed in January 2026, expanding the franchise in Colorado and Arizona with expectations of top‑tier share in Denver and a tripled Colorado branch count. A roughly $2B branch program to open 300+ locations by 2030 is underway, with dozens of new branches already opened in 2026.

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Investor Backing & Capital Strength: Trackers cite a September 7, 2023 Series A (about $10.8M, ~$16–17M total raised) that provides resources to scale products and field operations into utilities. This funding base supports the company’s post–Series A expansion efforts.

Innovation-Driven Growth: A patent granted on April 14, 2026 for autonomous scanning and digital tree-stand representation, together with a steady 2026 cadence of releases, indicates ongoing R&D investment. Updates such as a next‑gen backpack unit “shipped to customers,” pipeline automation, and expanded species ID suggest innovation translating into field adoption.

Market Expansion: Messaging and roles increasingly emphasize utility vegetation management and “keeping the grid running,” alongside multiple open roles across U.S. locations and a larger New York headquarters lease. These signals point to expansion from forestry into utilities amid regulatory and wildfire‑mitigation tailwinds.

Investor Backing & Capital Strength: A recent majority investment by a private equity sponsor is positioned to accelerate growth and provides capital for continued product and M&A activity. This backing signals confidence in the company’s long-term scale-up plan.

Innovation-Driven Growth: The company has launched new suites and AI-driven capabilities across compliance and decisioning, indicating ongoing R&D investment. This cadence points to a roadmap focused on modernizing GTN and market-access operations.

Strong Market Position & Advantage: It is widely regarded as a specialized leader in pharma net revenue and market access operations with an end-to-end platform. Scale claims and broad manufacturer adoption signals support this positioning, even if many are self-reported.

Investor Backing & Capital Strength: Feedback suggests top-tier insurer financial strength is affirmed and total adjusted surplus reached record levels in 2025, indicating strong claims-paying capacity. This capital position supports continued dividends and investment in growth initiatives.

Strong Market Position & Advantage: Feedback suggests the company is the clear scale leader within the U.S. fraternal benefit insurer segment by premiums. This niche leadership supports advice-led distribution and product breadth within its member-focused model.

Strong Brand Reputation: Feedback suggests repeated recognition for ethics and recurring Fortune 500 inclusion reinforce credibility and national-scale visibility. Such recognition supports client trust and enterprise stability.

Strong Market Position & Advantage: Fanatics is described as the category leader in licensed sports merchandise, operating official e‑commerce and in‑venue retail for major leagues and teams and being selected for major events retail like the 2026 FIFA World Cup. Through Fanatics Collectibles/Topps, long‑term and exclusive league licenses (e.g., MLB/MLBPA, NFL/NFLPA, NBA/NBPA, Premier League) reinforce a dominant collectibles position.

Strong Revenue Growth: Independent analyses indicate revenue of roughly $8.1 billion in 2024, reflecting mid‑teens year‑over‑year growth and continuing a multiyear climb. Commentary points to further gains into 2025–2026 alongside scaling newer lines.

Diversified Revenue Streams: The company spans commerce, collectibles, and sports betting, with newer initiatives like global events retail and Fanatics Studios broadening the base. Expansion beyond core apparel helps reduce reliance on a single line while adding incremental growth levers.

Strong Market Position & Advantage: Independent analyst recognitions and major enterprise adoption position PTC in the leader cohort for PLM (e.g., Forrester Leader placements, Gartner Critical Capabilities inclusion), with the U.S. Army selecting Windchill enterprise-wide. Portfolio breadth across PLM/CAD/ALM/SLM and integration along the digital thread reinforce competitive standing with large programs.

Strong Revenue Growth: Revenue grew double digits on a constant-currency basis in FY’25 and continued with 15%–21% growth in the first half of FY’26, indicating sustained top-line momentum despite portfolio changes. Management’s FY’26 outlook aligns with ongoing ARR expansion in the high‑single‑digit range on a comparable basis.

Healthy Cash Flow: Operating and free cash flow increased double digits in FY’25 and H1 FY’26, and guidance points to robust full‑year free cash flow. Significant share repurchases and new authorizations underscore strong cash generation and capital return capacity.

Strong Market Position & Advantage: Within care enablement and digital front door, the company is described as a category leader with unusually comprehensive coverage across triage, navigation, scheduling, virtual visits, and a 50‑state clinical network. Third‑party lists (CB Insights, DHNY, AVIA) and scale signals (relationships with 75+ health systems and 30,000 employers) suggest rising standing among peers.

Strong Revenue Growth: Company materials cite triple‑digit annual sales growth alongside ongoing product launches and new deployments through 2025–2026. Reported reach of roughly 100M covered lives and expanding enterprise relationships indicate accelerating topline momentum.

Investor Backing & Capital Strength: A $60M Series A in 2024 aligns with an aggressive build‑and‑buy strategy that includes multiple acquisitions over a short period. This funding posture supports continued platform development and distribution expansion.

Investor Backing & Capital Strength: New private equity sponsorship from Integrum and prior Audax backing underpin continued expansion through recapitalization and acquisitions. Company and investor disclosures describe material scaling under prior ownership with capital positioned to sustain growth.

Market Expansion: Multiple acquisitions (DebtX Analytics, Appraisers and Planners, Pointe Advisory) and new practice launches (e.g., ESOP Consulting, Strategy) show active geographic and service-line growth, including new offerings in Switzerland. Recent Year in Review data also indicate a larger platform serving more engagements and clients.

Strong Market Position & Advantage: Repeated top placements in LSEG fairness‑opinion rankings and IAM Patent 1000 recognition for numerous experts confirm leadership in core niches like U.S. fairness opinions and IP expert testimony. A large, dedicated ESOP practice further reinforces specialist strength.